Good news and bad news on a cholesterol treatment
Esperion Therapeutics yesterday published new data on its experimental cholesterol drug, bempedoic acid. And, as STAT’s Matt Herper reports, there’s good news: The drug reduced LDL cholesterol by more than 17 percent in 12 weeks and sustained those results for a full year.
There’s also less good news.
Doctors are still seeking answers on the drug’s side effects and safety. The whole idea behind the treatment is to offer it to patients who can’t take a statin because of side effects. But earlier studies have shown bempedoic acid comes with side effects of its own.
Read more.
There’s also less good news.
Doctors are still seeking answers on the drug’s side effects and safety. The whole idea behind the treatment is to offer it to patients who can’t take a statin because of side effects. But earlier studies have shown bempedoic acid comes with side effects of its own.
Read more.
No hay comentarios:
Publicar un comentario